JiShi Pharmaceutical -B (02616.HK): The Phase II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) has enrolled its first patient in Australia.

The Zhixin Finance and Economics App reports that Cornerstone Therapeutics -B (02616.HK) has announced that the global multicenter Phase II clinical trial of the company's core pipeline CS2009 (a specific antibody targeting PD-1/VEGF/CTLA-4) has enrolled its first patient in Australia. The trial is currently actively enrolling patients in Australia and China, and will expand to the United States in the future.